An Open-Label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients with Relapsed and/or Refractory Follicular Lymphoma

Study Status

Open to Enrollment

Study Description

This clinical trial is for men and women with follicular lymphoma who have either relapsed after taking standard treatments or did not respond to (refractory to) standard treatments. The study is evaluating an experimental drug called MLN9708. The purpose of the study is to determine the effectiveness of MLN9708 in treating relapsed/refractory follicular lymphoma.

MLN9708 is capsule taken by mouth. It is a type of drug called a proteasome inhibitor. Proteasome inhibitors work by inhibiting proteins that cells need to survive and multiply. Cancer cells are more susceptible to this effect than normal cells. Inhibiting these proteins (proteasomes) may help kill cancer cells. All study participants will receive MLN9708; there is no placebo. 

Treatment cycles are 28 days. Participants will take MLN9708 on Days 1, 8 and 15 of each cycle, followed by a rest period of 13 days. 

Participants will continue to receive MLN9708 for as long as they are responding to therapy and not experiencing unacceptable side effects.

Disease Status and/or Stage

Relapsed or refractory follicular lymphoma

Sponsor

Millennium Pharmaceuticals

Key Eligibility

  • Men and women age 18 and older
  • Diagnosed with follicular lymphoma
  • Relapsed and/or refractory after at least 1 prior therapy
  • Detailed eligibility reviewed when you contact the study team

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page